Angiographic Patterns of Restenosis With 2nd Generation Drug-Eluting Stent: Comparative Analysis from a 10-Year Single-Center Experience

The angiographic features of restenosis contain prognostic information. However, restenosis patterns of the new generation drug-eluting stents (DES), everolimus-(EES) and resolute zotarolimus-eluting stent (ZES) have not been described. A total of 210 consecutive patients with DES restenosis were en...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International Heart Journal 2015, Vol.56(1), pp.6-12
Hauptverfasser: Lee, Sahmin, Yoon, Chang-Hwan, Oh, Il-Young, Suh, Jung-Won, Cho, Young-Seok, Cho, Goo-Yeong, Chae, In-Ho, Choi, Dong-Ju, Youn, Tae-Jin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 12
container_issue 1
container_start_page 6
container_title International Heart Journal
container_volume 56
creator Lee, Sahmin
Yoon, Chang-Hwan
Oh, Il-Young
Suh, Jung-Won
Cho, Young-Seok
Cho, Goo-Yeong
Chae, In-Ho
Choi, Dong-Ju
Youn, Tae-Jin
description The angiographic features of restenosis contain prognostic information. However, restenosis patterns of the new generation drug-eluting stents (DES), everolimus-(EES) and resolute zotarolimus-eluting stent (ZES) have not been described. A total of 210 consecutive patients with DES restenosis were enrolled from 2003 to 2012. We analyzed 217 restenotic lesions after DES implantation, and compared the morphologic characteristics of the 2nd generation DES restenosis to those of restenosis with 2 first generation DES, sirolimus-(SES) and paclitaxel-eluting stent (PES). Baseline characteristics were comparable between the different stent groups. The incidence of focal restenosis was significantly lower for PES than the other stents (49.5% versus 87.0%, 76.2%, and 82.1% for PES versus SES, EES, and ZES, respectively, P < 0.001). When considering the pattern of restenosis solely within the stent margins, a further clear distinction between PES and other stents was observed (40.0% versus 92.9%, 88.9%, and 81.2% in PES versus SES, EES, and ZES, respectively, P < 0.001). There were no significant differences in restenosis patterns among SES, EES, and ZES. In multivariate analysis, PES implantation, hypertension, and age were associated with non-focal type of restenosis after DES implantation. After the introduction of EES and ZES into routine clinical practice in 2008, focal restenosis significantly increased from 63.9% to 76.7% and diffuse restenosis significantly decreased from 26.4% to 11.0% (P = 0.045). Focal restenosis was the most common pattern of restenosis in the new generation DES and the incidence of diffuse restenosis significantly decreased with the introduction of the 2nd generation DES.
doi_str_mv 10.1536/ihj.14-072
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1536_ihj_14_072</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>25503656</sourcerecordid><originalsourceid>FETCH-LOGICAL-c233t-ad082c1b2feb3e4924fcab293477f25da6f7a8de7f0d33b01364961efc06e3813</originalsourceid><addsrcrecordid>eNo9kE1PAjEQhhujEUQv_gDTs8liv7bL3iSIqCHR-BGPTbc7XUqgS9py8N-7AnKZmbzz5D08CF1TMqQ5l3dusRxSkZGCnaA-5aLMOCvL08PNuMx76CLGJSGC5qQ4Rz2W56SLZR-9jH3j2ibozcIZ_KZTguAjbi1-h5jAt9FF_O3SAjNf4xl4CDq51uOHsG2y6WqbnG_wR0emS3Rm9SrC1WEP0Nfj9HPylM1fZ8-T8TwzjPOU6ZqMmKEVs1BxECUT1uiKlVwUhWV5raUt9KiGwpKa84pQLkUpKVhDJPAR5QN0u-81oY0xgFWb4NY6_ChK1J8Q1QlRVKhOSAff7OHNtlpDfUT_DXTA_R5YxqQbOAI6JGdWsOvKpaK7ses8vsxCBwWe_wIdZXMv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Angiographic Patterns of Restenosis With 2nd Generation Drug-Eluting Stent: Comparative Analysis from a 10-Year Single-Center Experience</title><source>J-STAGE Free</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Lee, Sahmin ; Yoon, Chang-Hwan ; Oh, Il-Young ; Suh, Jung-Won ; Cho, Young-Seok ; Cho, Goo-Yeong ; Chae, In-Ho ; Choi, Dong-Ju ; Youn, Tae-Jin</creator><creatorcontrib>Lee, Sahmin ; Yoon, Chang-Hwan ; Oh, Il-Young ; Suh, Jung-Won ; Cho, Young-Seok ; Cho, Goo-Yeong ; Chae, In-Ho ; Choi, Dong-Ju ; Youn, Tae-Jin</creatorcontrib><description>The angiographic features of restenosis contain prognostic information. However, restenosis patterns of the new generation drug-eluting stents (DES), everolimus-(EES) and resolute zotarolimus-eluting stent (ZES) have not been described. A total of 210 consecutive patients with DES restenosis were enrolled from 2003 to 2012. We analyzed 217 restenotic lesions after DES implantation, and compared the morphologic characteristics of the 2nd generation DES restenosis to those of restenosis with 2 first generation DES, sirolimus-(SES) and paclitaxel-eluting stent (PES). Baseline characteristics were comparable between the different stent groups. The incidence of focal restenosis was significantly lower for PES than the other stents (49.5% versus 87.0%, 76.2%, and 82.1% for PES versus SES, EES, and ZES, respectively, P &lt; 0.001). When considering the pattern of restenosis solely within the stent margins, a further clear distinction between PES and other stents was observed (40.0% versus 92.9%, 88.9%, and 81.2% in PES versus SES, EES, and ZES, respectively, P &lt; 0.001). There were no significant differences in restenosis patterns among SES, EES, and ZES. In multivariate analysis, PES implantation, hypertension, and age were associated with non-focal type of restenosis after DES implantation. After the introduction of EES and ZES into routine clinical practice in 2008, focal restenosis significantly increased from 63.9% to 76.7% and diffuse restenosis significantly decreased from 26.4% to 11.0% (P = 0.045). Focal restenosis was the most common pattern of restenosis in the new generation DES and the incidence of diffuse restenosis significantly decreased with the introduction of the 2nd generation DES.</description><identifier>ISSN: 1349-2365</identifier><identifier>EISSN: 1349-3299</identifier><identifier>DOI: 10.1536/ihj.14-072</identifier><identifier>PMID: 25503656</identifier><language>eng</language><publisher>Japan: International Heart Journal Association</publisher><subject>Aged ; Angiography ; Angioplasty ; Coronary ; Coronary Angiography - methods ; Coronary Artery Disease - physiopathology ; Coronary Artery Disease - surgery ; Coronary Restenosis - diagnosis ; Coronary Restenosis - epidemiology ; Coronary Restenosis - etiology ; Coronary Vessels - pathology ; Coronary Vessels - physiopathology ; Drug-Eluting Stents - adverse effects ; Everolimus ; Female ; Humans ; Immunosuppressive Agents - therapeutic use ; Incidence ; Intervention ; Male ; Middle Aged ; Paclitaxel - therapeutic use ; Percutaneous Coronary Intervention - adverse effects ; Percutaneous Coronary Intervention - instrumentation ; Percutaneous Coronary Intervention - methods ; Postoperative Complications - diagnosis ; Postoperative Complications - epidemiology ; Registries ; Republic of Korea ; Sirolimus - analogs &amp; derivatives ; Sirolimus - therapeutic use ; Treatment Outcome ; Vascular Patency</subject><ispartof>International Heart Journal, 2015, Vol.56(1), pp.6-12</ispartof><rights>2015 by the International Heart Journal Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c233t-ad082c1b2feb3e4924fcab293477f25da6f7a8de7f0d33b01364961efc06e3813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,1877,4010,27904,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25503656$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Sahmin</creatorcontrib><creatorcontrib>Yoon, Chang-Hwan</creatorcontrib><creatorcontrib>Oh, Il-Young</creatorcontrib><creatorcontrib>Suh, Jung-Won</creatorcontrib><creatorcontrib>Cho, Young-Seok</creatorcontrib><creatorcontrib>Cho, Goo-Yeong</creatorcontrib><creatorcontrib>Chae, In-Ho</creatorcontrib><creatorcontrib>Choi, Dong-Ju</creatorcontrib><creatorcontrib>Youn, Tae-Jin</creatorcontrib><title>Angiographic Patterns of Restenosis With 2nd Generation Drug-Eluting Stent: Comparative Analysis from a 10-Year Single-Center Experience</title><title>International Heart Journal</title><addtitle>Int. Heart J.</addtitle><description>The angiographic features of restenosis contain prognostic information. However, restenosis patterns of the new generation drug-eluting stents (DES), everolimus-(EES) and resolute zotarolimus-eluting stent (ZES) have not been described. A total of 210 consecutive patients with DES restenosis were enrolled from 2003 to 2012. We analyzed 217 restenotic lesions after DES implantation, and compared the morphologic characteristics of the 2nd generation DES restenosis to those of restenosis with 2 first generation DES, sirolimus-(SES) and paclitaxel-eluting stent (PES). Baseline characteristics were comparable between the different stent groups. The incidence of focal restenosis was significantly lower for PES than the other stents (49.5% versus 87.0%, 76.2%, and 82.1% for PES versus SES, EES, and ZES, respectively, P &lt; 0.001). When considering the pattern of restenosis solely within the stent margins, a further clear distinction between PES and other stents was observed (40.0% versus 92.9%, 88.9%, and 81.2% in PES versus SES, EES, and ZES, respectively, P &lt; 0.001). There were no significant differences in restenosis patterns among SES, EES, and ZES. In multivariate analysis, PES implantation, hypertension, and age were associated with non-focal type of restenosis after DES implantation. After the introduction of EES and ZES into routine clinical practice in 2008, focal restenosis significantly increased from 63.9% to 76.7% and diffuse restenosis significantly decreased from 26.4% to 11.0% (P = 0.045). Focal restenosis was the most common pattern of restenosis in the new generation DES and the incidence of diffuse restenosis significantly decreased with the introduction of the 2nd generation DES.</description><subject>Aged</subject><subject>Angiography</subject><subject>Angioplasty</subject><subject>Coronary</subject><subject>Coronary Angiography - methods</subject><subject>Coronary Artery Disease - physiopathology</subject><subject>Coronary Artery Disease - surgery</subject><subject>Coronary Restenosis - diagnosis</subject><subject>Coronary Restenosis - epidemiology</subject><subject>Coronary Restenosis - etiology</subject><subject>Coronary Vessels - pathology</subject><subject>Coronary Vessels - physiopathology</subject><subject>Drug-Eluting Stents - adverse effects</subject><subject>Everolimus</subject><subject>Female</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Incidence</subject><subject>Intervention</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Paclitaxel - therapeutic use</subject><subject>Percutaneous Coronary Intervention - adverse effects</subject><subject>Percutaneous Coronary Intervention - instrumentation</subject><subject>Percutaneous Coronary Intervention - methods</subject><subject>Postoperative Complications - diagnosis</subject><subject>Postoperative Complications - epidemiology</subject><subject>Registries</subject><subject>Republic of Korea</subject><subject>Sirolimus - analogs &amp; derivatives</subject><subject>Sirolimus - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Vascular Patency</subject><issn>1349-2365</issn><issn>1349-3299</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1PAjEQhhujEUQv_gDTs8liv7bL3iSIqCHR-BGPTbc7XUqgS9py8N-7AnKZmbzz5D08CF1TMqQ5l3dusRxSkZGCnaA-5aLMOCvL08PNuMx76CLGJSGC5qQ4Rz2W56SLZR-9jH3j2ibozcIZ_KZTguAjbi1-h5jAt9FF_O3SAjNf4xl4CDq51uOHsG2y6WqbnG_wR0emS3Rm9SrC1WEP0Nfj9HPylM1fZ8-T8TwzjPOU6ZqMmKEVs1BxECUT1uiKlVwUhWV5raUt9KiGwpKa84pQLkUpKVhDJPAR5QN0u-81oY0xgFWb4NY6_ChK1J8Q1QlRVKhOSAff7OHNtlpDfUT_DXTA_R5YxqQbOAI6JGdWsOvKpaK7ses8vsxCBwWe_wIdZXMv</recordid><startdate>2015</startdate><enddate>2015</enddate><creator>Lee, Sahmin</creator><creator>Yoon, Chang-Hwan</creator><creator>Oh, Il-Young</creator><creator>Suh, Jung-Won</creator><creator>Cho, Young-Seok</creator><creator>Cho, Goo-Yeong</creator><creator>Chae, In-Ho</creator><creator>Choi, Dong-Ju</creator><creator>Youn, Tae-Jin</creator><general>International Heart Journal Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2015</creationdate><title>Angiographic Patterns of Restenosis With 2nd Generation Drug-Eluting Stent</title><author>Lee, Sahmin ; Yoon, Chang-Hwan ; Oh, Il-Young ; Suh, Jung-Won ; Cho, Young-Seok ; Cho, Goo-Yeong ; Chae, In-Ho ; Choi, Dong-Ju ; Youn, Tae-Jin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c233t-ad082c1b2feb3e4924fcab293477f25da6f7a8de7f0d33b01364961efc06e3813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Angiography</topic><topic>Angioplasty</topic><topic>Coronary</topic><topic>Coronary Angiography - methods</topic><topic>Coronary Artery Disease - physiopathology</topic><topic>Coronary Artery Disease - surgery</topic><topic>Coronary Restenosis - diagnosis</topic><topic>Coronary Restenosis - epidemiology</topic><topic>Coronary Restenosis - etiology</topic><topic>Coronary Vessels - pathology</topic><topic>Coronary Vessels - physiopathology</topic><topic>Drug-Eluting Stents - adverse effects</topic><topic>Everolimus</topic><topic>Female</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Incidence</topic><topic>Intervention</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Paclitaxel - therapeutic use</topic><topic>Percutaneous Coronary Intervention - adverse effects</topic><topic>Percutaneous Coronary Intervention - instrumentation</topic><topic>Percutaneous Coronary Intervention - methods</topic><topic>Postoperative Complications - diagnosis</topic><topic>Postoperative Complications - epidemiology</topic><topic>Registries</topic><topic>Republic of Korea</topic><topic>Sirolimus - analogs &amp; derivatives</topic><topic>Sirolimus - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Vascular Patency</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Sahmin</creatorcontrib><creatorcontrib>Yoon, Chang-Hwan</creatorcontrib><creatorcontrib>Oh, Il-Young</creatorcontrib><creatorcontrib>Suh, Jung-Won</creatorcontrib><creatorcontrib>Cho, Young-Seok</creatorcontrib><creatorcontrib>Cho, Goo-Yeong</creatorcontrib><creatorcontrib>Chae, In-Ho</creatorcontrib><creatorcontrib>Choi, Dong-Ju</creatorcontrib><creatorcontrib>Youn, Tae-Jin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>International Heart Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Sahmin</au><au>Yoon, Chang-Hwan</au><au>Oh, Il-Young</au><au>Suh, Jung-Won</au><au>Cho, Young-Seok</au><au>Cho, Goo-Yeong</au><au>Chae, In-Ho</au><au>Choi, Dong-Ju</au><au>Youn, Tae-Jin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Angiographic Patterns of Restenosis With 2nd Generation Drug-Eluting Stent: Comparative Analysis from a 10-Year Single-Center Experience</atitle><jtitle>International Heart Journal</jtitle><addtitle>Int. Heart J.</addtitle><date>2015</date><risdate>2015</risdate><volume>56</volume><issue>1</issue><spage>6</spage><epage>12</epage><pages>6-12</pages><issn>1349-2365</issn><eissn>1349-3299</eissn><abstract>The angiographic features of restenosis contain prognostic information. However, restenosis patterns of the new generation drug-eluting stents (DES), everolimus-(EES) and resolute zotarolimus-eluting stent (ZES) have not been described. A total of 210 consecutive patients with DES restenosis were enrolled from 2003 to 2012. We analyzed 217 restenotic lesions after DES implantation, and compared the morphologic characteristics of the 2nd generation DES restenosis to those of restenosis with 2 first generation DES, sirolimus-(SES) and paclitaxel-eluting stent (PES). Baseline characteristics were comparable between the different stent groups. The incidence of focal restenosis was significantly lower for PES than the other stents (49.5% versus 87.0%, 76.2%, and 82.1% for PES versus SES, EES, and ZES, respectively, P &lt; 0.001). When considering the pattern of restenosis solely within the stent margins, a further clear distinction between PES and other stents was observed (40.0% versus 92.9%, 88.9%, and 81.2% in PES versus SES, EES, and ZES, respectively, P &lt; 0.001). There were no significant differences in restenosis patterns among SES, EES, and ZES. In multivariate analysis, PES implantation, hypertension, and age were associated with non-focal type of restenosis after DES implantation. After the introduction of EES and ZES into routine clinical practice in 2008, focal restenosis significantly increased from 63.9% to 76.7% and diffuse restenosis significantly decreased from 26.4% to 11.0% (P = 0.045). Focal restenosis was the most common pattern of restenosis in the new generation DES and the incidence of diffuse restenosis significantly decreased with the introduction of the 2nd generation DES.</abstract><cop>Japan</cop><pub>International Heart Journal Association</pub><pmid>25503656</pmid><doi>10.1536/ihj.14-072</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1349-2365
ispartof International Heart Journal, 2015, Vol.56(1), pp.6-12
issn 1349-2365
1349-3299
language eng
recordid cdi_crossref_primary_10_1536_ihj_14_072
source J-STAGE Free; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Aged
Angiography
Angioplasty
Coronary
Coronary Angiography - methods
Coronary Artery Disease - physiopathology
Coronary Artery Disease - surgery
Coronary Restenosis - diagnosis
Coronary Restenosis - epidemiology
Coronary Restenosis - etiology
Coronary Vessels - pathology
Coronary Vessels - physiopathology
Drug-Eluting Stents - adverse effects
Everolimus
Female
Humans
Immunosuppressive Agents - therapeutic use
Incidence
Intervention
Male
Middle Aged
Paclitaxel - therapeutic use
Percutaneous Coronary Intervention - adverse effects
Percutaneous Coronary Intervention - instrumentation
Percutaneous Coronary Intervention - methods
Postoperative Complications - diagnosis
Postoperative Complications - epidemiology
Registries
Republic of Korea
Sirolimus - analogs & derivatives
Sirolimus - therapeutic use
Treatment Outcome
Vascular Patency
title Angiographic Patterns of Restenosis With 2nd Generation Drug-Eluting Stent: Comparative Analysis from a 10-Year Single-Center Experience
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T07%3A16%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Angiographic%20Patterns%20of%20Restenosis%20With%202nd%20Generation%20Drug-Eluting%20Stent:%20Comparative%20Analysis%20from%20a%2010-Year%20Single-Center%20Experience&rft.jtitle=International%20Heart%20Journal&rft.au=Lee,%20Sahmin&rft.date=2015&rft.volume=56&rft.issue=1&rft.spage=6&rft.epage=12&rft.pages=6-12&rft.issn=1349-2365&rft.eissn=1349-3299&rft_id=info:doi/10.1536/ihj.14-072&rft_dat=%3Cpubmed_cross%3E25503656%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/25503656&rfr_iscdi=true